Literature DB >> 2986291

Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients.

F Barin, M F McLane, J S Allan, T H Lee, J E Groopman, M Essex.   

Abstract

In this study, two glycoproteins (gp160 and gp120) that are encoded by human T-cell lymphoma virus type III (HTLV-III) were the antigens most consistently recognized by antibodies found in patients with the acquired immune deficiency syndrome (AIDS) and with the AIDS-related complex (ARC) and in healthy homosexual males. The techniques used to detect the glycoproteins were radioimmunoprecipitation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (RIP/SDS-PAGE). Although most antibody-positive samples from ARC patients and from healthy homosexual males also reacted with the virus core protein p24, less than half of the AIDS patients revealed a positive band with p24 under the same conditions. The ability to detect antibodies against a profile of both the major env gene encoded antigens and the gag gene encoded antigens suggests that the RIP/SDS-PAGE may be a valuable confirmatory assay for establishing the presence or absence of antibodies to HTLV-III in human serum samples.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2986291     DOI: 10.1126/science.2986291

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  72 in total

1.  Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env.

Authors:  L Gritz; A Destree; N Cormier; E Day; V Stallard; T Caiazzo; G Mazzara; D Panicali
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

2.  The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter.

Authors:  Rebecca M Lynch; Rong Rong; Saikat Boliar; Anurag Sethi; Bing Li; Joseph Mulenga; Susan Allen; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

3.  Coexpression of human immunodeficiency virus envelope proteins and tat from a single simian virus 40 late replacement vector.

Authors:  D Rekosh; A Nygren; P Flodby; M L Hammarskjöld; H Wigzell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

Review 4.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

5.  Development and evaluation of immunoassay for detection of antibodies to the feline T-lymphotropic lentivirus (feline immunodeficiency virus).

Authors:  T P O'Connor; S Tanguay; R Steinman; R Smith; M C Barr; J K Yamamoto; N C Pedersen; P R Andersen; Q J Tonelli
Journal:  J Clin Microbiol       Date:  1989-03       Impact factor: 5.948

6.  Expression of the human immunodeficiency virus envelope glycoprotein is restricted to basolateral surfaces of polarized epithelial cells.

Authors:  R J Owens; R W Compans
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

7.  Patterns of antigenaemia and antibody response in patients infected with human immunodeficiency virus (HIV) according to clinical state.

Authors:  M C Re; G Furlini; M La Placa
Journal:  J Clin Pathol       Date:  1989-03       Impact factor: 3.411

8.  Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein.

Authors:  S S Chen; C N Lee; W R Lee; K McIntosh; T H Lee
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  Risk factors for HIV seropositivity among people consulting for HIV antibody testing: a pilot surveillance study in Quebec.

Authors:  M Alary; J Castel
Journal:  CMAJ       Date:  1990-07-01       Impact factor: 8.262

10.  Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.

Authors:  Rong Rong; Bing Li; Rebecca M Lynch; Richard E Haaland; Megan K Murphy; Joseph Mulenga; Susan A Allen; Abraham Pinter; George M Shaw; Eric Hunter; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.